Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adult

01 Mar 20264 min read0 viewsJournal Feed

GIST

This study evaluates the cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease and potential effect on US health care spending.

Clinical Editorial

Summary

JAMA Cardiology published a clinical update in Cardiology on 01 Mar 2026.

The item focuses on Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

ClinicalTrialsRelated by Drugsemaglutide

Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies

Research Highlights • 21 May 2026

BMJ OpenRelated by Drugsemaglutide

Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial

Research Highlights • 20 May 2026

STATRelated by Drugsemaglutide

STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more

Research Highlights • 13 May 2026

Feed Metadata

Source

JAMA Cardiology